Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998476 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
A Phase 2 study of Lymphoma, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT02998476 is a Phase 2 study of Lymphoma that has completed, run by Incyte Corporation. The registered enrollment target is 60 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02998476, a Phase 2 study of Lymphoma, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Conditions Studied
Interventions
- DRUG Parsaclisib
Study Locations (20)
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Arizona Oncology Associates, PC - HAL - Tempe
California
- Sutter Gould Medical Foundation - Modesto
- Sharp Memorial Hospital - San Diego
Florida
- Advanced Pharma CR, LLC - Miami
- Asclepes Research Centers - Weeki Wachee
Indiana
- Indiana BMT - Beech Grove
- Parkview Research Center - Fort Wayne
Michigan
- Karmanos Cancer Institute - Detroit
- St. John Hospital and Medical Center - Detroit
New Jersey
- Summit Medical Group - Morristown
- Rutgers Cancer Institute of New Jersey - New Brunswick
Alabama
- University of Alabama at Birmingham - Birmingham
Illinois
- Advocate Medical Group Niles Milwaukee Ave - Niles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-03-02 |
| Est. Completion | 2021-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02998476
The ClinicalTrials.gov registry entry for NCT02998476 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Parsaclisib is the first listed.
NCT02998476 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02998476 about?
NCT02998476 is a clinical study titled "A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)". The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.
What is the current status of trial NCT02998476?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2017-03-02. Estimated completion is 2021-02-05.
What conditions does trial NCT02998476 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT02998476?
The interventions under investigation include: Parsaclisib (DRUG).
Who is sponsoring clinical trial NCT02998476?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02998476 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.